BioScience Health Innovations (BHIC) Debt to Equity (2019 - 2022)

BioScience Health Innovations (BHIC) has 4 years of Debt to Equity data on file, last reported at $0.38 in Q2 2022.

• Debt to Equity for Q2 2022 came in at $0.38, up 119.64% year-over-year; the trailing twelve-month figure through May 2022 was $0.38 (up 119.64% YoY), and the FY2021 annual result was -$1.36, down 323.55% from the prior year.
• Debt to Equity climbed to $0.38 in Q2 2022 per BHIC's latest filing, from $0.24 in the prior quarter.
• Over five years, Debt to Equity peaked at $3.22 in Q4 2019 and troughed at -$239.04 in Q1 2020.
• A 4-year average of -$23.89 and a median of -$0.08 in 2020 frame the typical range for Debt to Equity.
• The sharpest annual moves came in 2021 and 2022: Debt to Equity sank 369.01% in 2021, then jumped 119.64% in 2022.
• A 4-year view of Debt to Equity shows it stood at $3.22 in 2019, then tumbled by 39.48% to $1.95 in 2020, then tumbled by 87.76% to $0.24 in 2021, then soared by 57.49% to $0.38 in 2022.
• Business Quant data shows BHIC's Debt to Equity at $0.38 in Q2 2022, $0.24 in Q4 2021, and -$1.36 in Q3 2021.